Matthew Okkerse Portfolio
Invests via Dauntless Investment Group LLC | Managed by Matthew Okkerse
Invests via Dauntless Investment Group LLC
Managed by Matthew Okkerse
Automatically Tracked
Private markets investor and operator focused on growth-stage technology and services businesses. Matthew Okkerse is known for leading deal sourcing, due diligence and portfolio value creation at mid-sized buyout and growth equity funds, and engages with LPs on strategy and reporting. Experienced in financial planning, operations and go-to-market scaling, he has overseen add-on acquisitions and exit readiness. Background includes roles in corporate finance and strategy and academic credentials in economics and finance. Market-facing strengths include cross-border sourcing, operational improvement and capital structuring.
Private markets investor and operator focused on growth-stage technology and services businesses. Matthew Okkerse is known for leading deal sourcing, due diligence and portfolio value creation at mid-sized buyout and growth equity funds, and engages with LPs on strategy and reporting. Experienced in financial planning, operations and go-to-market scaling, he has overseen add-on acquisitions and exit readiness. Background includes roles in corporate finance and strategy and academic credentials in economics and finance. Market-facing strengths include cross-border sourcing, operational improvement and capital structuring.
Investment Philosophy & Strategy
Focuses on growth-stage technology and services companies, blending buyout rigor with growth-equity agility. Emphasizes active, operationally-driven value creation: go-to-market scaling, FP&A-led performance improvement, and accretive add-on M&A. Underwrites opportunities with cross-border sourcing advantages and pragmatic capital-structure solutions to balance growth funding and downside protection. Prefers mid-market situations where hands-on governance, exit planning, and management alignment accelerate EBITDA conversion. Time horizon is multi-year with staged capital deployment and clear operational KPIs guiding follow-on investments and exit timing.
Focuses on growth-stage technology and services companies, blending buyout rigor with growth-equity agility. Emphasizes active, operationally-driven value creation: go-to-market scaling, FP&A-led performance improvement, and accretive add-on M&A. Underwrites opportunities with cross-border sourcing advantages and pragmatic capital-structure solutions to balance growth funding and downside protection. Prefers mid-market situations where hands-on governance, exit planning, and management alignment accelerate EBITDA conversion. Time horizon is multi-year with staged capital deployment and clear operational KPIs guiding follow-on investments and exit timing.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
18.51%
Gain +0.45%
Monthly
0.86%
Yearly
10.79%
Drawdown
25.21%
$50.73M
Equity
Holdings
$50.73M
Investment
$56.33M
$2.03M
Profit +$418,285.36
Realized
$7.63M
Unrealized
-$5.6M
Dividends
$332,420.45
Goals
Avg. 19% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
0.45%
Profit
$418,285.36
Win %
40%
This Week
Compared To Last Week
Gain
3.34%
Profit
$1.63M
Win %
40%
This Month
Compared to last month
Gain
3.44%
Profit
$1.68M
Win %
40%
This Year
Compared to last year
Gain
-12.46%
Profit
-$7.19M
Win %
43%
MRX
MRX
+58.89%
+$233,219.36 
AIRS AirSculpt Technologies Inc.
+4%
+$8,756.8 
VLO Valero Energy Corporation
+3.85%
+$134,980.31 
TOI The Oncology Institute Inc.
+0.65%
+$6,542.8 
TRAW Traws Pharma Inc.
+0.58%
+$249.78 
CALM Cal-Maine Foods Inc.
+0.46%
+$980.78 
SNDA Sonida Senior Living Inc.
+0.46%
+$633.78 
AEON Aeon Biopharma Inc.
0%
-$0.12 
AEM Agnico Eagle Mines Limited
0%
$0 
APYX Apyx Medical Corporation
0%
$0 
ARMP Armata Pharmaceuticals Inc.
0%
$0 
AZTR Azitra Inc.
0%
-$0.11 
BKD Brookdale Senior Living Inc.
0%
$0 
CAPR Capricor Therapeutics Inc.
0%
$0 
CGTX Cognition Therapeutics Inc.
0%
$0 
CIB Bancolombia S.A.
0%
$0 
COUR Coursera Inc.
0%
$0 
CRESY Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria - American Depositary Receipt
0%
$0 
CRIS Curis Inc.
0%
$0 
DC Dakota Gold Corp
0%
$0 
DRTS Alpha Tau Medical Ltd.
0%
$0 
ESTA Establishment Labs Holdings Inc.
0%
$0 
FEMY Femasys Inc.
0%
$0 
GGAL Grupo Financiero Galicia S.A. ADR
0%
$0 
INMB Inmune Bio Inc.
0%
$0 
INVA Innoviva Inc.
0%
$0 
IRS IRSA Inversiones y Representaciones Sociedad Anónima
0%
$0 
JAN JanOne Inc
0%
$0 
JOE The St. Joe Company
0%
$0 
KZIA Kazia Therapeutics Ltd Sponsored ADR
0%
$0 
LCTX Lineage Cell Therapeutics Inc.
0%
$0 
LINC Lincoln Educational Services Corporation
0%
$0 
LOMA Loma Negra C.I.A.S.A. Sponsored ADR
0%
$0 
MLP Maui Land & Pineapple Company, Inc.
0%
$0 
MOB Mobilicom Ltd.
0%
$0 
MPC Marathon Petroleum Corporation
0%
$0 
NOW ServiceNow, Inc.
0%
$0 
PPC Pilgrim's Pride Corporation
0%
$0 
PROF Profound Medical Corp.
0%
$0 
PTCT PTC Therapeutics, Inc.
0%
$0 
QNRX Quoin Pharmaceuticals Ltd. - American Depositary Receipt
0%
$0 
STIM Neuronetics Inc.
0%
$0 
TLSA Tiziana Life Sciences Ltd.
0%
-$0.01 
TRVI Trevi Therapeutics Inc.
0%
$0 
UNCY Unicycive Therapeutics Inc.
0%
$0 
UPWK Upwork Inc.
0%
$0 
UTI Universal Technical Institute Inc.
0%
$0 
WELL Welltower Inc.
0%
$0 
PPLT abrdn Physical Platinum Shares ETF
0%
$0 
TLPH Talphera Inc.
0%
$0 
DSL DoubleLine Income Solutions Fund
0%
$0 
HSAI Hesai Group American Depositary Share
0%
$0 
CCXI ChemoCentryx Inc
0%
$0 
TVA Texas Ventures Acquisition Corp.
0%
$0 
RTAC Renatus Tactical Acquisition Corp.
0%
$0 
JBS JBS N.V.
0%
$0 
COLO Global X MSCI Colombia ETF
0%
$0 
AEXA American Exceptionalism Acquisition Corp. A
0%
$0 
NWAX-UN New America Acquisition I Corp.
0%
$0 HCAC
HCAC
0%
$0 
Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 355 | Longs Won 170/355 47% | Profit Factor 1.12 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $303,578.07 |
| Average Win $122,799.95 | Best Trade (Dec 31) $1.34M | Sharpe Ratio -30.84 |
| Average Loss -$100,619.99 | Worst Trade (Aug 20) -$5.19M | Z-Score -1.99 (98.47%) |
| Commissions $0 | Avg. Trade Length 5m 1w 2d | Expectancy $5,712.88 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | 0.05% | 0.31% | 1.28% | 4.02% | 10.61% | 24.57% | 51.54% |
| Consecutive Losing Trades | 504 | 454 | 403 | 353 | 302 | 252 | 202 | 151 | 101 | 50 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
 ADAG Adagene Inc. | 537,230 | $2.25M | $2M | - | -$248,133.4 | -11.04% | -0.8% |
| AEM Agnico Eagle Mines Limited | 165 | $27,812.4 | $30,554.7 | - | $2,742.3 | 9.86% | 0.0 |
| AEON Aeon Biopharma Inc. | 12.49M | $9.33M | $3.43M | - | -$5.9M | -63.2% | 0.0 |
| AEXA American Exceptionalism Acquisition Corp. A | 670 | $7,631.31 | $7,772 | - | $140.69 | 1.84% | 0.0 |
| AIRS AirSculpt Technologies Inc. | 67,360 | $303,118.33 | $227,676.8 | - | -$75,441.53 | -24.89% | +4% |
| APYX Apyx Medical Corporation | 30,249 | $135,818 | $90,444.51 | - | -$45,373.49 | -33.41% | 0.0 |
| ARMP Armata Pharmaceuticals Inc. | 203,891 | $1.64M | $878,770.21 | - | -$758,745.83 | -46.34% | 0.0 |
| AZTR Azitra Inc. | 11.29M | $2.24M | $1.52M | - | -$711,443.72 | -31.82% | 0.0 |
| BKD Brookdale Senior Living Inc. | 4,571 | $73,547 | $59,331.58 | - | -$14,215.42 | -19.33% | 0.0 |
| CALM Cal-Maine Foods Inc. | 2,581 | $204,286.14 | $213,164.79 | - | $8,878.65 | 4.35% | +0.462% |
| CAPR Capricor Therapeutics Inc. | 1 | $30.4 | $4.19 | - | -$26.21 | -86.22% | 0.0 |
| CCXI ChemoCentryx Inc | 38,587 | $673,343 | $624,723.53 | - | -$48,619.47 | -7.22% | 0.0 |
| CGTX Cognition Therapeutics Inc. | 371,701 | $501,796.35 | $386,569.04 | - | -$115,227.31 | -22.96% | 0.0 |
| CIB Bancolombia S.A. | 443 | $35,187 | $42,434.97 | - | $7,247.97 | 20.6% | 0.0 |
| COLO Global X MSCI Colombia ETF | 507 | $21,117 | $24,427.26 | - | $3,310.26 | 15.68% | 0.0 |
| COUR Coursera Inc. | 224,171 | $1.35M | $1.25M | - | -$103,546.63 | -7.65% | 0.0 |
| CRESY Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria - American Depositary Receipt | 80,186 | $898,885 | $857,990.2 | - | -$40,894.8 | -4.55% | 0.0 |
| CRIS Curis Inc. | 500.05 | $5,500.55 | $835.08 | - | -$4,665.47 | -84.82% | 0.0 |
| DC Dakota Gold Corp | 581 | $2,934.05 | $3,642.87 | - | $708.82 | 24.16% | 0.0 |
| DRTS Alpha Tau Medical Ltd. | 61,200 | $769,896 | $848,844 | - | $78,948 | 10.25% | 0.0 |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Matthew Okkerse?
The largest contributions to the portfolio's profits come from the following stocks: Northern Dynasty Minerals Ltd - $1.4M, Adecoagro S.A - $1.26M, Lincoln Educational Services Corporation - $1.24M, Okyo Pharma Ltd - $978,712.42, and Lineage Cell Therapeutics Inc - $943,760.82. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Femasys Inc - $2.41M, Myomo Inc - $661,943.65, Traws Pharma Inc - $331,949.53, Inmune Bio Inc - $219,985.77, and TScan Therapeutics Inc - $183,172.9. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Matthew Okkerse's portfolio generate?
The portfolio generates substantial dividend income, with a total of $332,420.45 earned over time. The largest contributors to dividend income include Vale S.A - $43,161.01, Valero Energy Corporation - $23,890.82, The St. Joe Company - $23,784.48, JBS N.V - $21,308, and PBF Energy Inc - $19,576.99. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Matthew Okkerse's monthly returns?
Matthew Okkerse's monthly returns appear quite volatile. The gap between stronger and weaker months is meaningful, which suggests that the strategy can experience noticeable swings over relatively short periods. For users assessing this profile, that usually means returns may be attractive over time, but the path can be uneven and harder to tolerate during weaker periods.
Can Matthew Okkerse's strategy be considered aggressive or moderate?
Matthew Okkerse's strategy can be described as moderate. It balances growth potential with risk management, showing a willingness to accept some volatility while still maintaining a relatively structured and diversified approach.
Should beginners follow Matthew Okkerse's strategy?
Matthew Okkerse's strategy is probably not ideal for beginners. The combination of risk, volatility, or portfolio complexity may make it harder to follow and understand without prior experience. Users who are new to investing may find it challenging to replicate or tolerate the performance swings.
